Volume 56, Issue 2, Pages (August 1999)

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

Increased expression of heparanase in overt diabetic nephropathy

Volume 54, Issue 2, Pages (August 1998)

Volume 82, Issue 2, Pages (July 2012)

Volume 54, Issue 2, Pages (August 1998)

Volume 56, Pages S54-S56 (July 1999)

Volume 58, Issue 4, Pages (October 2000)

C. J. Ilse Raats, Jacob Van Den Born, Jo.H.M. Berden, M.D., Ph.D.

Jean-Claude Davin, Ineke J. Ten Berge, Jan J. Weening

Volume 76, Issue 5, Pages (September 2009)

Volume 68, Issue 2, Pages (August 2005)

Volume 80, Issue 10, Pages (November 2011)

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

Sickle Cell Nephropathy

Volume 66, Issue 3, Pages (September 2004)

Kamyar Kalantar-Zadeh Kidney International

Tubular biomarkers to assess progression of diabetic nephropathy

Yang Wang, Yi Ping Wang, Yuet-Ching Tay, David C.H. Harris

Estimation of podocyte number: A comparison of methods

Volume 57, Issue 1, Pages (January 2000)

Volume 74, Issue 3, Pages (August 2008)

Volume 60, Issue 6, Pages (December 2001)

Volume 63, Issue 4, Pages (April 2003)

Targets to retard the progression of diabetic nephropathy

Volume 73, Issue 7, Pages (April 2008)

Volume 56, Issue 3, Pages (September 1999)

Volume 87, Issue 2, Pages (February 2015)

The role of protein kinase C activation in diabetic nephropathy

The calcium–phosphorus in guidelines for CKD-MBD

Volume 53, Issue 5, Pages (May 1998)

Volume 75, Issue 1, Pages (January 2009)

Volume 56, Issue 5, Pages (November 1999)

Volume 70, Issue 8, Pages (October 2006)

Volume 76, Issue 5, Pages (September 2009)

Volume 65, Issue 4, Pages (April 2004)

Volume 81, Issue 5, Pages (March 2012)

Hypertension, race, and glomeruli: more than simply a numbers game

Volume 63, Issue 1, Pages (January 2003)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Red cell traverse through thin glomerular basement membranes

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Michael W. Steffes, Derek Schmidt, Rebecca Mccrery, John M. Basgen

Tatsumi Moriya, Thomas J. Groppoli, Youngki Kim, Michael Mauer

Volume 60, Issue 1, Pages (July 2001)

Volume 80, Issue 3, Pages (August 2011)

Antiglomerular basement membrane disease with normal renal function

Volume 57, Issue 5, Pages (May 2000)

Volume 69, Issue 2, Pages (January 2006)

The role of heparan sulfate in the glomerular basement membrane

Volume 80, Issue 10, Pages (November 2011)

Volume 58, Issue 1, Pages (July 2000)

Sandra Blanco, Rosa Penin, Irma Casas, Dolores López, Ramón Romero

Volume 70, Issue 3, Pages (August 2006)

Volume 63, Issue 1, Pages (January 2003)

Amylin deposition in the kidney of patients with diabetic nephropathy

Volume 69, Issue 3, Pages (February 2006)

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Volume 56, Issue 4, Pages (October 1999)

Membranous nephropathy: recent travels and new roads ahead

Volume 55, Issue 3, Pages (March 1999)

Volume 63, Issue 6, Pages (June 2003)

Volume 58, Issue 5, Pages (November 2000)

Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status Kathryn J. Tinckam, Ognjenka Djurdjev, Alex.

Lipoprotein abnormalities in diabetic nephropathy

Laura M. Krinsky, William J. Levine Kidney International

Renoprotection with vitamin D: Specific for diabetic nephropathy?

Glomerular binding of anti-dsDNA autoantibodies: The dispute resolved?

Volume 57, Issue 1, Pages (January 2000)

Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis Eero O. Honkanen, Anna-Maija Teppo, Carola.

Presentation transcript:

Volume 56, Issue 2, Pages 650-658 (August 1999) Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy Hiroki Yokoyama, Ken Sato, Maki Okudaira, Chihiro Morita, Chieko Takahashi, Daisuke Suzuki, Hideto Sakai, Yasuhiko Iwamoto Kidney International Volume 56, Issue 2, Pages 650-658 (August 1999) DOI: 10.1046/j.1523-1755.1999.00591.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Fluid phase inhibition of 10E4 biding to chemically modified heparan sulfate (HS). Symbols are: (•) HS, heparan sulfate containing N-sulfate, 6-O-sulfate, and 2-O-sulfate; (▪) CDSNAc-HS, completely desulfated, N-acetylated HS; (▴) CDSNS-HS, completely desulfated, N-sulfated HS; (X) NDSNAc-HS, N-desulfated, N-acetylated HS. Kidney International 1999 56, 650-658DOI: (10.1046/j.1523-1755.1999.00591.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Immunohistochemical staining with heparan sulfate (HS) 10E4 antibody. (A) A glomerulus from a nondiabetic subject that demonstrates a linear staining pattern in the glomerular basement membrane and mesangial area (×400, score = 4). (B) A glomerulus from a patient with diabetic nephropathy with moderate mesangial expansion that shows diminished staining (×400, score = 2). (C) A glomerulus from a patient with diabetic nephropathy with severe mesangial expansion that shows that the staining intensity was totally diminished (×400, score = 0). Kidney International 1999 56, 650-658DOI: (10.1046/j.1523-1755.1999.00591.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 Score of intensity of human glomeruli stained immunohistochemically with heparan sulfate (HS) 10E4 antibody in nondiabetic subjects (subjects 1 through 3), diabetic subjects with normoalbuminuria (subjects 4 through 6) and overt proteinuria (subjects 7 through 11). Data are mean ±sem. Kidney International 1999 56, 650-658DOI: (10.1046/j.1523-1755.1999.00591.x) Copyright © 1999 International Society of Nephrology Terms and Conditions